FDA
-
-
-
-
-
-
-
Protagonist Therapeutics Announces U.S. FDA Approval of Hepcidin Mimetic Peptide MIMRYLO(TM) (rusfertide) for Polycythemia Vera
-
-
-
-
-
-
-
Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026
-
-
-
-
-
-
-
Protagonist Therapeutics (PTGX) PT Raised to $119 at Barclays following Icotyde approval
-
-
-
-
-
-
-
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
-
-
-
-
-
-
-
After-hours movers: J&J gains on another talc settlement, InflaRx adds on FDA EUA
-
330,524 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

